- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- 10.4 License, Development and Commercialization Agreement Between the Registrant (As Assigned to It by Ampio/vyrix) and Daewoong Pharmaceuticals Co., LTD., Effective As of August 23, 2011
- 10.11 Voting Agreement Between the Registrant and Ampio, Dated April 21, 2015
- 10.31 Amended and Restated Exclusive License Agreement, Dated June 11, 2018, Between AYTU Bioscience, Inc. and Magna Pharmaceuticals, Inc.
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- Download Excel data file
- View Excel data file
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Aytu BioScience, Inc.’s Registration Statements on Form S-8 (File No. 333-205462), Form S-3 (File No. 333-221735) and Form S-1 (File Nos. 333-207421, 333-205414, 333-209874, 333-210144, 333-212100, 333-213738, 333-213489, 333-220351, 333-222994, and 333-223385) of our report dated September 6, 2018, relating to the consolidated financial statements that appear in this Annual Report on Form 10-K.
Our report dated September 6, 2018 contains an explanatory paragraph that states that the Company's recurring losses from operations and accumulated deficit raise substantial doubt about the Company's ability to continue as a going concern, as discussed in Note 3 to the consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.
/s/ EKS&H LLLP |
September 6, 2018 |
Denver, Colorado |